We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The multikinase inhibitor EC‐70124 synergistically increased the antitumor activity of doxorubicin in sarcomas.
- Authors
Estupiñan, Oscar; Santos, Laura; Rodriguez, Aida; Fernandez‐Nevado, Lucia; Costales, Paula; Perez‐Escuredo, Jhudit; Hermosilla, Maria Ana; Oro, Patricia; Rey, Veronica; Tornin, Juan; Allonca, Eva; Fernandez‐Garcia, Maria Teresa; Alvarez‐Fernandez, Carlos; Braña, Alejandro; Astudillo, Aurora; Menendez, Sofia T; Moris, Francisco; Rodriguez, Rene
- Abstract
Cytotoxic drugs like doxorubicin remain as the most utilized agents in sarcoma treatment. However, advanced sarcomas are often resistant, thus stressing the need for new therapies aimed to overcome this resistance. Multikinase inhibitors provide an efficient way to target several pro‐tumorigenic pathways using a single agent and may constitute a valuable strategy in the treatment of sarcomas, which frequently show an aberrant activation of pro‐tumoral kinases. Therefore, we studied the antitumor activity of EC‐70124, an indolocarbazole analog that have demonstrated a robust ability to inhibit a wide range of pro‐survival kinases. Evaluation of the phospho‐kinase profile in cell‐of‐origin sarcoma models and/or sarcoma primary cell lines evidenced that PI3K/AKT/mTOR, JAK/STAT or SRC were among the most highly activated pathways. In striking contrast with the structurally related drug midostaurin, EC‐70124 efficiently prevented the phosphorylation of these targets and robustly inhibited proliferation through a mechanism associated to the induction of DNA damage, cell cycle arrest and apoptosis. In addition, EC‐70124 was able to partially reduce tumor growth in vivo. Importantly, this compound inhibited the expression and activity of ABC efflux pumps involved in drug resistance. In line with this ability, we found that the combined treatment of EC‐70124 with doxorubicin resulted in a synergistic cytotoxic effect in vitro and an increased antitumor activity of this cytotoxic drug in vivo. Altogether, these results uncover the capability of the novel multikinase inhibitor EC‐70124 to counteract drug resistance in sarcoma and highlight its therapeutic potential when combined with current treatments. What's new? Wide‐spectrum multi‐kinase inhibitors may help forestall the onset of drug resistance in cancer. In this paper, the authors tested one such inhibitor, called EC‐70124, in sarcoma cells. Sarcoma is typically treated with doxorubicin, but advanced sarcomas often develop resistance by way of ABC transporters, which pump the drug out of the cell. Here, the authors showed that EC‐70124 not only slowed tumor growth in vivo, it inhibited the ABC pumps associated with resistance. EC‐70124 also worked synergistically with doxorubicin for increased anti‐tumor activity.
- Publication
International Journal of Cancer, 2019, Vol 145, Issue 1, p254
- ISSN
0020-7136
- Publication type
Article
- DOI
10.1002/ijc.32081